OVERVIEW

Community Practice Connections™: 3rd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application is organized by Physicians' Education Resource, LLC (PER) and will be held from Feb 28, 2019 - Feb 28, 2020.

Target Audience:
This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving role in the treatment of cancer.

Accreditation/Credit Designation:
• CME: 2.0
• CNE: 2.0

Activity Overview:
Community Practice Connections™: 3rd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune-based therapies in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts, and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapies.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer
• Evaluate clinical trial findings on immuno-oncology (I-O) strategies, and how they can be practically applied to the management of cancer in multiple lines of care
• Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of I-O strategies
• Describe how common and uncommon adverse events, associated with the use of I-O strategies, can be proactively mitigated and managed
• Detail important remaining clinical questions in the field and highly anticipated ongoing clinical trials that are evaluating emerging I-O strategies

Additional details will be posted as soon as they are available.